T. J. Yao

870 total citations
17 papers, 667 citations indexed

About

T. J. Yao is a scholar working on Oncology, Pathology and Forensic Medicine and Cancer Research. According to data from OpenAlex, T. J. Yao has authored 17 papers receiving a total of 667 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 5 papers in Pathology and Forensic Medicine and 5 papers in Cancer Research. Recurrent topics in T. J. Yao's work include Cancer Treatment and Pharmacology (8 papers), Breast Cancer Treatment Studies (4 papers) and Hepatocellular Carcinoma Treatment and Prognosis (3 papers). T. J. Yao is often cited by papers focused on Cancer Treatment and Pharmacology (8 papers), Breast Cancer Treatment Studies (4 papers) and Hepatocellular Carcinoma Treatment and Prognosis (3 papers). T. J. Yao collaborates with scholars based in United States, China and Japan. T. J. Yao's co-authors include Andrew D. Seidman, Clifford A. Hudis, John Crown, Teresa Gilewski, J. McCarthy Lepore, Violante E. Currie, Amy Tiersten, Sophie Barrett, Larry Norton and Antonella Surbone and has published in prestigious journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.

In The Last Decade

T. J. Yao

17 papers receiving 646 citations

Peers

Countries citing papers authored by T. J. Yao

Since Specialization

Citations

This map shows the geographic impact of T. J. Yao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by T. J. Yao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites T. J. Yao more than expected).

Fields of papers citing papers by T. J. Yao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by T. J. Yao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by T. J. Yao. The network helps show where T. J. Yao may publish in the future.

Co-authorship network of co-authors of T. J. Yao

This figure shows the co-authorship network connecting the top 25 collaborators of T. J. Yao. A scholar is included among the top collaborators of T. J. Yao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with T. J. Yao. T. J. Yao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	An oncolytic virus–delivered TGFβ inhibitor overcomes the immunosuppressive tumor microenvironment 2023 ·The Journal of Experimental Medicine ·Kristin DePeaux, Dayana B. Rivadeneira, Konstantinos Lontos, (unknown), William G. Gunn, McLane J. Watson, T. J. Yao, (unknown), Cynthia S. Hinck, Łukasz Wieteska, Stephen H. Thorne, Andrew P. Hinck, Greg M. Delgoffe	20
2	Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease 2012 ·Investigational New Drugs ·Thomas Yau, Hilda Wong, Pierre Chan, T. J. Yao, Richard Pang, Tan To Cheung, Sheung Tat Fan, Ronnie T.P. Poon	59
3	The use of single-agent sorafenib in the treatment of patients with advanced hepatocellular carcinoma with underlying Child-Pugh B liver cirrhosis. 2011 ·Journal of Clinical Oncology ·Joanne Chiu, (unknown), T. J. Yao, April S. Y. Wong, Herman Wong, Roland Leung, (unknown), Tan To Cheung, (unknown), Song Fan, CC Yau	1
4	Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial 2010 ·BMJ ·Eric Chen, Christy Lai Ming Hui, (unknown), Cindy P.Y. Chiu, C.W. Law, Dicky W. S. Chung, S.K. Tso, (unknown), K.T. Chan, (unknown), (unknown), (unknown), T. J. Yao, S. F. Hung, William G. Honer	105
5	Efficacy and tolerability of sorafenib in elderly patients with advanced hepatocellular carcinoma. 2010 ·Journal of Clinical Oncology ·(unknown), CC Yau, T. J. Yao, Victor Tang, (unknown), (unknown), Song Fan, (unknown)	1
6	5-Year Results of Dose-Intensive Sequential Adjuvant Chemotherapy for Women With High-Risk Node-Positive Breast Cancer: A Phase II Study 1999 ·Journal of Clinical Oncology ·Clifford A. Hudis, Monica Fornier, (unknown), David Lebwohl, John Crown, Theresa Gilewski, Antonella Surbone, Violante E. Currie, Andrew D. Seidman, Bonnie Reichman, Mary Ellen Moynahan, George Raptis, Nancy T. Sklarin, Maria Theodoulou, Lora Weiselberg, Rori Salvaggio, K. Panageas, T. J. Yao, Larry Norton	43
7	Sequential Dose-Dense Doxorubicin, Paclitaxel, and Cyclophosphamide for Resectable High-Risk Breast Cancer: Feasibility and Efficacy 1999 ·Journal of Clinical Oncology ·Clifford A. Hudis, Andrew D. Seidman, José Baselga, George Raptis, David Lebwohl, Teresa Gilewski, Mary Ellen Moynahan, Nancy T. Sklarin, D. Fennelly, John Crown, Antonella Surbone, Mary Uhlenhopp, Elyn Riedel, T. J. Yao, Larry Norton	86
8	Improved prognosis of solid‐type poorly differentiated colorectal adenocarcinoma: a clinicopathological and immunohistochemical study 1997 ·Histopathology ·(unknown), T. J. Yao, Chiharu Kubo, M Tsuneyoshi	26
9	Phase II study of semisynthetic paclitaxel in metastatic breast cancer 1997 ·European Journal of Cancer ·Clifford A. Hudis, (unknown), Frankie A. Holmes, Andrew D. Seidman, José Baselga, Violante E. Currie, D. Fennelly, Teresa Gilewski, Mary Ellen Moynahan, George Raptis, Nancy T. Sklarin, Antonella Surbone, Mary Uhlenhopp, (unknown), T. J. Yao, (unknown), (unknown), Gabriel N. Hortobágyi, Larry Norton	5
10	Effects of prior therapy on the in vitro proliferative potential of stem cell factor plus filgrastim-mobilized CD34-positive progenitor cells. 1997 ·PubMed ·F.L. Shapiro, T. J. Yao, Craig H. Moskowitz, Lillian Reich, David Wuest, (unknown), I K McNiece, (unknown), Stephen D. Nimer, M A Moore	11
11	Jejunal Myoepithelial Hamartoma Associated with Gardner's Syndrome: A Case Report 1996 ·Endoscopy ·Kazuoki Hizawa, Mitsuo lida, Kenta Aoyagi, Ryuichi Mibu, T. J. Yao, Masatoshi Fujishima	8
12	Association between thyroid cancer of cribriform variant and familial adenomatous polyposis. 1996 ·Journal of Clinical Pathology ·Kazuoki Hizawa, Mitsuo Iida, T. J. Yao, Kenta Aoyagi, Yoshihiro Oohata, Ryuichi Mibu, Koji Yamasaki, (unknown), Masatoshi Fujishima	25
13	Quality of Life in Phase II Trials: a Study of Methodology and Predictive Value in Patients With Advanced Breast Cancer Treated With Paclitaxel Plus Granulocyte Colony-Stimulating Factor 1995 ·JNCI Journal of the National Cancer Institute ·Andrew D. Seidman, Russell K. Portenoy, T. J. Yao, J. McCarthy Lepore, Erik K. Mont, Jeremy Kortmansky, N Onetto, Lei Ren, (unknown), Mohan Beltangady, (unknown), (unknown), Collette Houston, Mary S. McCabe, Rori Salvaggio, H. Tzvi Thaler, Larry Norton	85
14	Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. 1995 ·Journal of Clinical Oncology ·Andrew D. Seidman, Amy Tiersten, Clifford A. Hudis, (unknown), Sophie Barrett, T. J. Yao, J. McCarthy Lepore, Teresa Gilewski, Violante E. Currie, John Crown	177
15	Taxol (Paclitaxel) plus Recombinant Human Granulocyte Colony-Stimulating Factor in the Treatment of Metastatic Breast Cancer 1994 ·Oncology ·Andrew D. Seidman, Larry Norton, Bonnie Reichman, John Crown, T. J. Yao, Thomas B. Hakes, David Lebwohl, Theresa Gilewski, Clifford A. Hudis, Antonella Surbone, Violante E. Currie, Raymond W. Klecker, Carlos Jamis‐Dow, Jerry M. Collins, (unknown), (unknown), (unknown), Renzo Canetta, Nicole Onetto, Susan G. Arbuck	2
16	Taxol and Recombinant Human Granulocyte Colony‐Stimulating Factor, an Active Regimen as Initial Therapy for Metastatic Breast Cancer 1993 ·Annals of the New York Academy of Sciences ·Bonnie Reichman, Andrew D. Seidman, John Crown, Robert T. Heelan, T. J. Yao, Thomas B. Hakes, David Lebwohl, Theresa Gilewski, Antonella Surbone, Violante E. Currie, Clifford A. Hudis, (unknown), (unknown), (unknown), Renzo Canetta, Jason S. Fisherman, Susan G. Arbuck, Larry Norton	2
17	Over-expression of transforming growth factor alpha antagonizes the anti-tumorigenic but not the differentiation actions of retinoic acid in a human teratocarcinoma cell. 1993 ·PubMed ·José Baselga, (unknown), (unknown), W. H. Miller, Larissa Moreira Spinola de Castro Raucci, Victor E. Reuter, T. J. Yao, Hideo Masui, Ethan Dmitrovsky	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact